Hyplaxy

Hydroxychloroquine, the active ingredient in Hyplaxy, is a 4‑aminoquinoline antimalarial presented as an oral tablet for oral use. It treats malaria, rheumatoid arthritis and systemic lupus erythematosus in adult patients.

GNH USA supplies Hyplaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation for global distribution.

Hydroxychloroquine is used in several disease categories, primarily infectious and autoimmune conditions.

Malaria: clears blood-stage parasites and prevents disease recurrence. Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Systemic lupus erythematosus: decreases disease activity and flares.

Hydroxychloroquine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset or vomiting. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Retinopathy: progressive vision loss that may be irreversible. - Cardiac toxicity: arrhythmias or cardiomyopathy. - Severe hypoglycemia: especially in diabetic patients.

When prescribing hydroxychloroquine, clinicians should consider several precautionary measures to minimize risk.

- Baseline ophthalmologic exam: assess retinal health before therapy. - Monitor blood glucose: watch for hypoglycemia in diabetic patients. - Assess cardiac function: avoid in patients with known QT prolongation. - Review renal and hepatic function: dose may need adjustment in impairment. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Hydroxychloroquine interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption. - Certain antiarrhythmic agents (e.g., quinidine): increase risk of cardiac toxicity. - CYP2D6 inhibitors (e.g., fluoxetine): raise plasma levels.

Moderate Interactions (Monitor Closely): - Digoxin: may increase serum concentrations. - Insulin or oral hypoglycemics: potentiate hypoglycemic effect. - Azithromycin: additive QT prolongation risk. - Rifampin: may decrease hydroxychloroquine levels.